Inclusion Criteria:

- Histologic confirmation of Multiple Myeloma

- Patients intended to be treated with myeloablative therapy and autologous
hematopoetic stem-cell transplant within one month of stem-cell collection

- Patients whose stem-cell mobilization regimen includes G-CSF (granulocyte-colony
stimulating factor)

- Males or non-pregnant females, who are 18 years of age or older

- Karnofsky score of ≥70%

Exclusion Criteria:

- Patients with pre-mobilization platelet count < 75,000/µL

- Patients who have received pelvic bone marrow irradiation as part of their
conditioning therapy

- Patients who have had a previous hematopoetic stem-cell transplant

- Patients who have had a previous hematopoetic stem-cell collection failure

- Impaired cardiac function, as evidenced by left ventricular ejection fraction <40%.

- Impaired hepatic function, as evidenced by alanine transaminase >2.5 x normal

- Impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon
monoxide (adjusted for patient hematocrit, if indicated) or forced expiratory volume
in 1 second <50% of predicted

- Impaired renal function, as evidenced by a creatinine clearance < 40 mL/min

- Impaired coagulation, as evidenced by a prothrombin time (PT) > twice normal

- Pregnancy or lactation

- Seropositivity for Human Immunodeficiency Virus-1/2, Hepatitis B Virus, or Hepatitis
C Virus

- Documented bacterial or fungal infection that requires intravenous antibiotics to be
started or continued while undergoing apheresis collection on the Spectra Optia
device

- Subjects enrolled in study protocols that could affect number of CD34+ cells
(pluripoten hematopoetic stem stells) collected or kinetics of neutrophil recovery

- Altered mental status, as evidenced by the inability to provide effective informed
consent